{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:10:56Z","timestamp":1763035856027},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2004,1,9]],"date-time":"2004-01-09T00:00:00Z","timestamp":1073606400000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the prevalence and clinical correlation of anti\u2010DNA topoisomerase II\u03b1 (anti\u2013topo II\u03b1) antibody in patients with localized scleroderma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Anti\u2013topo II\u03b1 antibodies or anti\u2010DNA topoisomerase I (topo I) antibodies were determined by enzyme\u2010linked immunosorbent assay (ELISA) and immunoblotting. Inhibition of topo II\u03b1 enzymatic activity by the antibodies was evaluated by decatenation assays using kinetoplast DNA as a substrate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>IgG or IgM anti\u2013topo II\u03b1 antibody was detected in 76% (35 of 46) of patients with localized scleroderma, and in 85% (11 of 13) of patients with generalized morphea, the severest form of localized scleroderma. This prevalence of the antibody in patients with localized scleroderma was much higher than that found in patients with systemic sclerosis (SSc) (5 of 37 [14%]), systemic lupus erythematosus (2 of 26 [8%]), dermatomyositis (2 of 20 [10%]), and in healthy controls (3 of 42 [7%]). Immunoblotting confirmed the presence of IgG anti\u2013topo II\u03b1 antibody in sera from patients with localized scleroderma and showed no cross\u2010reactivity of anti\u2013topo II\u03b1 antibody with topo I. Anti\u2013topo I antibody was not detected by ELISA in any sera from patients with localized scleroderma. In addition, anti\u2013topo I antibody from SSc patients did not cross\u2010react with topo II\u03b1. The presence of anti\u2013topo II\u03b1 antibody was associated with a greater total number of sclerotic lesions and number of plaque lesions in patients with localized scleroderma. Furthermore, anti\u2013topo II\u03b1 antibody was able to inhibit topo II\u03b1 enzymatic activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results of the present study indicate that anti\u2013topo II\u03b1 is a major autoantibody in localized scleroderma, and is distinct from anti\u2013topo I antibody in SSc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.11432","type":"journal-article","created":{"date-parts":[[2004,1,13]],"date-time":"2004-01-13T12:02:17Z","timestamp":1073995337000},"page":"227-232","source":"Crossref","is-referenced-by-count":53,"title":["Anti\u2010DNA topoisomerase II\u03b1 autoantibodies in localized scleroderma"],"prefix":"10.1002","volume":"50","author":[{"given":"Ikuko","family":"Hayakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,1,9]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780360815"},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/archderm.1994.01690100057009","article-title":"Antigen specificity of antihistone antibodies in localized scleroderma","volume":"130","author":"Sato S","year":"1994","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00747.x"},{"key":"e_1_2_5_5_2","first-page":"184","article-title":"Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease","volume":"76","author":"Meliconi R","year":"1989","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01320.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.45.4.408"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1991.tb08156.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(89)90067-0"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780251101"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.765"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118851"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.80.14.4374"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.11432","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.11432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:29:17Z","timestamp":1698712157000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.11432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1002\/art.11432"],"URL":"https:\/\/doi.org\/10.1002\/art.11432","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}